Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

J Neuroimmunol. 2021 Dec 15;361:577746. doi: 10.1016/j.jneuroim.2021.577746. Epub 2021 Oct 9.

Abstract

Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100%), treated with Cladribine (N = 48, 100%), Dimethyl fumarate (N = 35, 100%), Natalizumab (N = 32, 100%), and Teriflunomide (N = 39, 100%), similarly to healthy subjects (N = 89, 97.8%). Response was decreased in Fingolimod (N = 42, 9.5%), Ocrelizumab (N = 114, 22.8%) and Alemtuzumab (N = 22, 86.4%) treated patients. IgG response can help tailor adequate vaccine guidelines for MS patients under various DMTs.

Keywords: COVID-19; Disease modifying treatments; Humoral immunity; IgG antibody; Multiple sclerosis; Vaccination.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Antibodies, Viral / blood*
  • Antirheumatic Agents / therapeutic use
  • BNT162 Vaccine / immunology*
  • COVID-19 / prevention & control*
  • Cross-Sectional Studies
  • Female
  • Humans
  • Immunity, Humoral / immunology*
  • Immunoglobulin G / blood
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / immunology*
  • Prospective Studies
  • SARS-CoV-2

Substances

  • Antibodies, Viral
  • Antirheumatic Agents
  • Immunoglobulin G
  • Immunosuppressive Agents
  • BNT162 Vaccine